Ranbaxy, Dr Reddy’s to benefit from tax sops - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy, Dr Reddy’s to benefit from tax sops

May 4, 2000

The government has granted full tax exemption (for a period of ten years) for inflows from milestone payments received by pharmaceutical companies on the sale of New Chemical Entities (NCE) and Novel Drug Delivery Systems (NDDS). This exemption currently stands at 50% of the payments received. Besides, the existing tax benefit of 125% of expenditure on R&D has been increased to 150%. This will further serve as a major incentive to the domestic pharma companies to invest in research as the cumulative tax benefit on such investments amounts to 57.75% (Corporate tax rate – 38.5% factored 1.50 times amounts to 57.75%).

Since the multinational companies do not carry out research in the country it will be the domestic pharmaceutical companies who will benefit from this move. Notable among these are Ranbaxy and Dr Reddy’s Laboratories (DRL).

Ranbaxy, for instance, received US $ 10 m (Rs 435 m) last year when it signed the deal with Bayer. Over the next 24–30 months the company would receive another $ 50 m (Rs 2,175 m) apart from a royalty of 10% on the sales of the new dosage form by Bayer. All these incomes would be tax–free.

Similarly, DRL has three new original molecules in its research pipeline. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future.

Any deal DRL enters into is likely to be modeled along the lines it has with the Danish company Novo Nordisk which is developing DRL’s diabetes lead molecules. The company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

Notable among the other beneficiaries are Cipla, Sun Pharma and Nicholas Piramal, which also have aggressive plans in the NCE segment.


Equitymaster requests your view! Post a comment on "Ranbaxy, Dr Reddy’s to benefit from tax sops". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

I Believe These Stocks Will Deliver the Most Outsized Returns in 2021 and Beyond (Profit Hunter)

Sep 23, 2020

Rules of the racetrack can help you bag the biggest gainers of the coming decade.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS